PrideStaff Named to Staffing Industry Analysts' List of Largest U.S. Staffing Firms for 13th Consecutive Year
The 2025 report includes 225 staffing companies, each of which generated at least $100 million in U.S. staffing revenue in 2024, a threshold fewer firms met than in previous years. According to SIA, these firms collectively represent 76.5% of the U.S. market by revenue, reflecting the ongoing consolidation and intense competition in the staffing industry.
Despite economic fluctuations and a cooling labor market in many sectors, PrideStaff sustained its national growth trajectory, strengthened its franchise network, and deepened its focus on delivering exceptional service to clients and talent alike. PrideStaff's 2024 performance builds on its momentum as a leading United States staffing provider. With over 80 offices across North America, the organization continues to expand its footprint while innovating in technology, candidate experience, and workforce strategy.
"It's incredibly rewarding to see our team's hard work recognized on SIA's list for the 13th straight year," said Tammi Heaton, PrideStaff Co-CEO. "This achievement reflects the adaptability of our model, the tenacity of our Owners/Strategic-Partners, and the full commitment of every team member across the nation to Our Mission: 'Consistently provide client experiences focused on what they value most.' This is especially important when workforce challenges are at their most complex."
About PrideStaff PrideStaff was founded in the 1970s as 100% company-owned units and began franchising in 1995. It operates offices in North America to serve thousands of clients and is headquartered in Central California. With 45-plus years in the staffing business, PrideStaff offers the resources and expertise of a national firm, with the spirit, dedication, and personal service of smaller, entrepreneurial firms. PrideStaff is the only nationwide commercial staffing firm in the U.S. and Canada with over $100 million in annual revenue to earn ClearlyRated's prestigious Best of Staffing® 15-Year Diamond Awards two years in a row, highlighting exceptional client and talent service quality.
For more information on our services, or staffing franchise information, visit our website.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pridestaff-named-to-staffing-industry-analysts-list-of-largest-us-staffing-firms-for-13th-consecutive-year-302481353.html
SOURCE Pridestaff, Inc
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Made-in-China.com's Golden Sourcing Season Sparks Global Procurement Momentum
NANJING, China, Aug. 18, 2025 /PRNewswire/ -- a leading global B2B platform, has kicked off its annual Golden Sourcing Season, running from August 1 to 31, giving international buyers a month-long opportunity to connect with verified Chinese suppliers, secure competitive deals, and source efficiently across diverse categories. Now in its fifth year, the event is already generating strong results. In its opening week, buyers from Turkey, Brazil, Vietnam, and the United States have closed trial orders, expanded purchase volumes, and discovered new suppliers through the platform's upgraded sourcing tools and multi-language marketplace. In Paraguay, a pharmaceutical company tripled its initial order from 100,000 to 300,000 packaging units after a targeted supplier match and real-time video negotiation. In Vietnam, importers finalized their first agricultural food purchase within days, demonstrating the efficiency of the platform's "source-to-shipment" support. data shows that in the first week alone, overall buyer visits rose 23.9% year-on-year. Strong demand came from industrial machinery, transport equipment, building materials, apparel accessories, consumer goods, and electronics. During the event, suppliers actively prepared and significantly improved their response speed, effectively shortening communication and negotiation cycles, while steadily boosting the speed and efficiency of global sourcing. The 2025 Golden Sourcing Season brings an enhanced experience for global buyers. Localized marketplaces in English, Spanish, Portuguese, French, and other languages provide tailored product recommendations based on regional demand. The Source Manufacturers pavilion is one of themed pavilions at Golden Sourcing Season, designed to connect buyers with the right suppliers efficiently. Featuring the "Leading Factory" service, it highlights top-tier manufacturers that meet rigorous standards in innovation, supply chain reliability, or production capacity. Buyers can access quality products at factory-direct prices, work directly with OEM/ODM factories, request samples, negotiate terms, and enjoy fast delivery. The AI assistant, AI Mic, designed for suppliers, is available free of charge during the event and helps refine product content while maintaining round-the-clock engagement with buyers. To maximize sourcing opportunities, is implementing a four-channel promotion strategy that covers on-platform exposure, global digital marketing, social communities, and offline exhibitions. With targeted exposure, vetted suppliers, and end-to-end trade support, the Golden Sourcing Season is set to keep global procurement momentum high throughout August, helping buyers source smarter, faster, and with greater confidence. Media Contact:YICHUN WU399779@ +86 02566677777 View original content to download multimedia: SOURCE
Yahoo
an hour ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Nordson Electronics Solutions 將於 SEMICON Taiwan 2025 展示面板級與晶圓級封裝的高產量流體點膠技術
加州卡爾斯巴德--(BUSINESS WIRE)--(美國商業資訊)-- Nordson Electronics Solutions 作為全球可靠電子製造技術的領導者，將於 9 月 10 至 12 日在 SEMICON Taiwan 2025 的 i2326 展位，展示其最新的 半導體製造設備 。 展品包括 ASYMTEK ® Vantage ® 點膠系統 ，配置兩個 ASYMTEK IntelliJet ® 噴射閥 ，專為半導體封裝及微電子製造提供高效精準的生產方案。Vantage 系統提供多種創新配置，以滿足當前技術發展需求，例如面板級封裝。該系統已廣泛應用於晶圓級封裝作業，包括高產量底部填充、間隙填充，以及適用於扇出/扇入、基板及模組組裝的密封生產線。 等離子處理可去除雜質並活化表面，增強流動性與附著力，從而提升半導體封裝的可靠性。Nordson 等離子處理專家將在現場與客戶探討，如何利用該技術成功實現先進封裝作業。 SEMICON Taiwan 2025 的主題為 「世界同行，創新啟航」，將展示半導體社群如何應對供應鏈變化，以及業界如何為當前與未來開發解決方案。 Nordson Electronics Solutions 致力讓可靠電子產品成為現實。我們透過 ASYMTEK、MARCH 及 SELECT 品牌，為全球半導體、電子及精密組裝製造商，提供創新的 流體點膠 、 表面塗覆 、 等離子處理 及 選擇性焊接 解決方案，保護敏感電子元件並提供可靠的使用壽命。四十多年來，在全球範圍內提供卓越的工程和應用服務，協助客戶取得成功。 關於 Nordson 公司 Nordson Corporation（NASDAQ：NDSN）是一家創新型精密技術的公司，通過一個以部門為主導的創業型組織，利用可擴展的成長框架，以領先的利潤和回報實現頂級增長。公司依託直接銷售模式和應用專業知識，透過各種關鍵應用為全球客戶提供服務。其多元化的終端市場包括非耐用消費品、醫療、電子和工業終端市場。公司創立於1954年，總部位於美國俄亥俄州韋斯特萊克，目前在全球35個國家/地區設有運營網站和技術支援辦公室。造訪Nordson官方網站： 。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
